The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khramilin V.N.

Pirogov Russian National Research Medical University (Pirogov University)

Davydov O.S.

Institute of General Pathology and Pathophysiology

Yakhno N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Kukushkin M.L.

Institute of General Pathology and Pathophysiology

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University)

Amelin A.V.

Academian I.P. Pavlov First Saint Petersburg State Medical University

Gurieva I.V.

Russian Medical Academy of Postgraduate Education

Ekusheva E.V.

Federal Scientific and Clinical Center for Specialized Medical Care and Medical Technologies

Rachin A.P.

National Association of Experts in Comorbid Neurology

Strokov I.A.

Sechenov First Moscow State Medical University (Sechenov University)

Suponeva N.A.

Research Center of Neurology and Neuroscience

Algorithm for the diagnosis and treatment of patients with diabetic polyneuropathy. Expert Council Resolution (March 1, 2025)

Authors:

Khramilin V.N., Davydov O.S., Yakhno N.N., Kukushkin M.L., Churyukanov M.V., Amelin A.V., Gurieva I.V., Ekusheva E.V., Rachin A.P., Strokov I.A., Suponeva N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8): 102‑113

DOI: 10.17116/jnevro2025125081102

Read: 2109 times

Buy for 300₽
Contact the author
Table of contents

ALGORITHM FOR THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH DIABETIC POLYNEUROPATHY. EXPERT COUNCIL RESOLUTION (MARCH 1, 2025)
ALGORITHM FOR THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH DIABETIC POLYNEUROPATHY. EXPERT COUNCIL RESOLUTION (MARCH 1, 2025)

To cite this article:

Khramilin VN, Davydov OS, Yakhno NN, et al. Algorithm for the diagnosis and treatment of patients with diabetic polyneuropathy. Expert Council Resolution (March 1, 2025). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8):102‑113. (In Russ.)
https://doi.org/10.17116/jnevro2025125081102

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Cere­brovascular disease in clinical practice. Reso­lution of the Expert Council of the Russian Scientific Medi­cal Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111
Painful diabetic poly­neuropathy in patients with cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):64-72
Pharmacological correction of burning eye syndrome. Russian Annals of Ophthalmology. 2025;(2):51-58
Features of comprehensive treatment in a patient with complicated type 2 diabetes mellitus: A clinical case. Piro­gov Russian Journal of Surgery. 2025;(6):128-132
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Late complications and quality of life after multivisceral surgeries with pancreatoduodenectomy. Piro­gov Russian Journal of Surgery. 2025;(7):36-45
Abstract:

The Expert Council has developed an algorithm for the diagnosis, treatment, and follow-up of patients with diabetes mellitus complicated by diabetic polyneuropathy (DPN), intended for use in both outpatient and inpatient settings. Particular emphasis is placed on the importance of early detection of DPN and interdisciplinary collaboration among specialists. The proposed algorithm includes recommendations for screening, clinical and instrumental diagnostics, risk stratification, and therapy selection based on the neuropathy phenotype, as well as the staged application of pathogenetic and symptomatic treatments, criteria for evaluating effectiveness, and indications for therapy continuation or adjustment. Experts highlighted the pathogenetic rationale for prescribing agents with neuroprotective and co-analgesic effects, including ipidacrine, which has proven efficacy and a legal basis for use in DPN. The algorithm promotes the standardization of care and can be integrated into the clinical practice of primary care physicians, endocrinologists, and neurologists.

Keywords:

diabetes mellitus
diabetic polyneuropathy
painful neuropathy
neuroprotective therapy
ipidacrine

Authors:

Khramilin V.N.

Pirogov Russian National Research Medical University (Pirogov University)

Davydov O.S.

Institute of General Pathology and Pathophysiology

Yakhno N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Kukushkin M.L.

Institute of General Pathology and Pathophysiology

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University)

Amelin A.V.

Academian I.P. Pavlov First Saint Petersburg State Medical University

Gurieva I.V.

Russian Medical Academy of Postgraduate Education

Ekusheva E.V.

Federal Scientific and Clinical Center for Specialized Medical Care and Medical Technologies

Rachin A.P.

National Association of Experts in Comorbid Neurology

Strokov I.A.

Sechenov First Moscow State Medical University (Sechenov University)

Suponeva N.A.

Research Center of Neurology and Neuroscience

Received:

10.07.2025

Accepted:

24.07.2025

Close metadata

References:

  1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.  https://doi.org/10.2337/dc16-2042
  2. Wang W, Ji Q, Ran X, et al. Prevalence and Risk Factors of Diabetic Peripheral Neuropathy: A Population-Based Cross-Sectional Study in China. Diabetes Metab Res Rev. 2023;39(8):e3702. https://doi.org/10.1002/dmrr.3702
  3. Lu Y, Xing P, Cai X, et al. Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study. Front Pub Health. 2020;8:534372. https://doi.org/10.3389/fpubh.2020.534372
  4. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes Mellitus in the Russian Federation: Dynamics of Epidemiological Indicators According to the Federal Diabetes Register Data for 2010—2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.). https://doi.org/10.14341/DM13035
  5. Zhou P, Zhou JS, Li JJ, et al. Prevalence and Risk Factors for Painful Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Front Neurol. 2025;16:1564867. https://doi.org/10.3389/fneur.2025.1564867
  6. Schaper N, Tölle T, Truini A, et al. Diagnosis, Management and Impact of Painful Diabetic Peripheral Neuropathy: A Patient Survey in Four European Countries. J Diabetes Compl. 2023;37(4):108417. https://doi.org/10.1016/j.jdiacomp.2023.108417
  7. Yakhno NN, Kukushkin ML, Davydov OS, et al. Results of the Russian Epidemiological Study on the Prevalence of Neuropathic Pain, Its Causes and Characteristics in the Population of Patients Visiting a Neurologist. Pain. 2008;3:24-32. (In Russ.).
  8. Wei KS, Gu MZ, Zhu JW, et al. Current Views of Diabetic Peripheral Neuropathic Pain Comorbid Depression: A Review. Eur Rev Med Pharmacol Sci. 2020;24(20):10663-10670. https://doi.org/10.26355/eurrev_202010_23424
  9. Gylfadottir SS, Christensen DH, Nicolaisen SK, et al. Diabetic Polyneuropathy and Pain, Prevalence, and Patient Characteristics: A Cross-Sectional Questionnaire Study of 5,514 Patients With Recently Diagnosed Type 2 Diabetes. Pain. 2020;161(3):574-583.  https://doi.org/10.1097/j.pain.0000000000001744
  10. Armstrong DG, Tan TW, Boulton AJM, et al. Diabetic Foot Ulcers: A Review. JAMA. 2023;330(1):62-75.  https://doi.org/10.1001/jama.2023.10578
  11. Bourron O. Artériopathie chez le patient diabétique. Rev Prat. 2019;69(6):620-625. (In French).
  12. Schaper NC, van Netten JJ, Apelqvist J, et al. Practical Guidelines on the Prevention and Management of Diabetic Foot Disease (IWGDF 2019 Update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3266. https://doi.org/10.1002/dmrr.3266
  13. Bokan-Mirković V, Škarić-Karanikić Ž, Nejkov S, et al. Diabetic Polyneuropathy and Risk of Falls: Fear of Falling and Other Factors. Acta Clin Croat. 2017;56(4):721-727.  https://doi.org/10.20471/acc.2017.56.04.20
  14. Vági OE, Svébis MM, Domján BA, et al. The Association Between Distal Symmetric Polyneuropathy in Diabetes With All-Cause Mortality: A Meta-Analysis. Front Endocrinol (Lausanne). 2023;14:1079009. https://doi.org/10.3389/fendo.2023.1079009
  15. Ziegler D. Diabetic Cardiovascular Autonomic Neuropathy: Prognosis, Diagnosis and Treatment. Diabetes Metab Rev. 1994;10(4):339-383.  https://doi.org/10.1002/dmr.5610100403
  16. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670-1690. https://doi.org/10.2337/dci22-0014
  17. Dyck PJ, Albers JW, Andersen H, et al. Diabetic Polyneuropathies: Update on Research Definition, Diagnostic Criteria and Estimation of Severity. Diabetes Metab Res Rev. 2011;27(7):620-628.  https://doi.org/10.1002/dmrr.1226
  18. Albers JW, Pop-Busui R. Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473.  https://doi.org/10.1007/s11910-014-0473-5
  19. Boulton AJ, Gries FA, Jervell JA. Guidelines for the Diagnosis and Outpatient Management of Diabetic Peripheral Neuropathy. Diabet Med. 1998;15(6):508-514.  https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L
  20. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285-2293. https://doi.org/10.2337/dc10-1303
  21. Khramilin VN, Strokov IA, Davydov OS, Churyukanov MV. Diagnosis of Diabetic Polyneuropathy in Primary Health Care. Russian Journal of Pain. 2021;19(2):47-59. (In Russ.). https://doi.org/10.17116/pain20211902147
  22. Laughlin RS, Dyck PJ. Diabetic Radiculoplexus Neuropathies. Handb Clin Neurol. 2014;126:45-52.  https://doi.org/10.1016/B978-0-444-53480-4.00004-7
  23. Strokov IA. Diabeticheskaja nevropatija. V kn.: «Jendokrinologija: Rukovodstvo dlja vrachej» pod red. VV. Potemkina. M.: OOO Izdatel’stvo «Medicinskoe informacionnoe agentstvo». 2013;385-401. (In Russ.).
  24. Samakidou G, Eleftheriadou I, Tentolouris A, et al. Rare Diabetic Neuropathies: It Is Not Only Distal Symmetrical Polyneuropathy. Diabetes Res Clin Pract. 2021;177:108932. https://doi.org/10.1016/j.diabres.2021.108932
  25. Smith BE. Focal and Entrapment Neuropathies. Handb Clin Neurol. 2014;126:31-43.  https://doi.org/10.1016/B978-0-444-53480-4.00003-5
  26. Pourmemari MH, Shiri R. Diabetes as a Risk Factor for Carpal Tunnel Syndrome: A Systematic Review and Meta-Analysis. Diabet Med. 2016;33(1):10-16.  https://doi.org/10.1111/dme.12855
  27. Rydberg M, Zimmerman M, Gottsäter A, et al. Diabetes Mellitus as a Risk Factor for Compression Neuropathy: A Longitudinal Cohort Study From Southern Sweden. BMJ Open Diabetes Res Care. 2020;8(1):e001298. https://doi.org/10.1136/bmjdrc-2020-001298
  28. Sharma KR, Cross J, Farronay O, et al. Demyelinating Neuropathy in Diabetes Mellitus. Arch Neurol. 2002;59(5):758-765.  https://doi.org/10.1001/archneur.59.5.758
  29. Chiò A, Plano F, Calvo A, et al. Comorbidity Between CIDP and Diabetes Mellitus: Only a Matter of Chance? Eur J Neurol. 2009;16(6):752-754.  https://doi.org/10.1111/j.1468-1331.2009.02598.x
  30. Bril V, Blanchette CM, Noone JM, et al. The Dilemma of Diabetes in Chronic Inflammatory Demyelinating Polyneuropathy. J Diab Compl. 2016;30(7):1401-1407. https://doi.org/10.1016/j.jdiacomp.2016.05.007
  31. Rajabally YA, Peric S, Cobeljic M, et al. Chronic Inflammatory Demyelinating Polyneuropathy Associated with Diabetes: A European Multicentre Comparative Reappraisal. J Neurol Neurosurg Psychiatry. 2020;91(10):1100-1104. https://doi.org/10.1136/jnnp-2020-322971
  32. Gibbons CH, Freeman R. Treatment-Induced Neuropathy of Diabetes: An Acute, Iatrogenic Complication of Diabetes. Brain. 2015;138(1):43-52.  https://doi.org/10.1093/brain/awu307
  33. Gibbons CH. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep. 2017;17(12):127.  https://doi.org/10.1007/s11892-017-0960-6
  34. Pop-Busui R, Ang L, Boulton AJM, et al. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy. Arlington, Va.: American Diabetes Association. 2022. https://doi.org/10.2337/db2022-01
  35. Zuidema X, de Galan B, Brouwer B, et al. Painful Diabetic Polyneuropathy. Pain Pract. 2024;24(2):308-320.  https://doi.org/10.1111/papr.13308
  36. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes Mellitus Type 1 in Adults. Diabetes Mellitus. 2020;23(1S):42-114. (In Russ.). https://doi.org/10.14341/DM12505
  37. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes Mellitus Type 2 in Adults. Diabetes Mellitus. 2020;23(2S):4-102. (In Russ.). https://doi.org/10.14341/DM12507
  38. Kirthi V, Perumbalath A, Brown E, et al. Prevalence of Peripheral Neuropathy in Pre-Diabetes: A Systematic Review. BMJ Open Diabetes Res Care. 2021;9(1):e002040. https://doi.org/10.1136/bmjdrc-2020-002040
  39. Klinicheskie rekomendacii ROIB. Diabeticheskaja distal’naja simmetrichnaja polinevropatija, 2023. (In Russ.).
  40. Galstyan GR, Starostina EG, Yakhno NN, et al. Diagnosis and Rational Treatment of Painful Diabetic Peripheral Neuropathy: An Interdisciplinary Expert Consensus. Diabetes Mellitus. 2019;22(4):305-327. (In Russ.). https://doi.org/10.14341/DM9625
  41. Khramilin VN, Davydov OS. Painful Diabetic Polyneuropathy: Diagnosis and Treatment from the Perspective of Evidence-Based Medicine. Russian Journal of Pain. 2021;19(4):44-59. (In Russ.). https://doi.org/10.17116/pain20211904144
  42. Tesfaye S, Vileikyte L, Rayman G, et al. Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management. Diabetes Metab Res Rev. 2011;27(7):629-638.  https://doi.org/10.1002/dmrr.1225
  43. Ziegler D, Keller J, Maier C, et al. Diabetische Neuropathie. Diab Stoffwec. 2019;14(Suppl 2):S243-S257. https://doi.org/10.1055/a-0899-0129
  44. Price DD, McGrath PA, Rafii A, et al. The Validation of Visual Analogue Scales as Ratio Scale Measures for Chronic and Experimental Pain. Pain. 1983;17:45-56.  https://doi.org/10.1016/0304-3959(83)90126-4
  45. Von Korff M, Jensen MP, Karoly P. Assessing global pain severity by self-report in clinical and health services research. Spine (Phila Pa 1976). 2000;25(24):3140-3151. https://doi.org/10.1097/00007632-200012150-00009
  46. Singleton JR, Smith AG, Bromberg MB. Increased Prevalence of Impaired Glucose Tolerance in Patients with Painful Sensory Neuropathy. Diabetes Care. 2001;24(8):1448-1453. https://doi.org/10.2337/diacare.24.8.1448
  47. Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015;38(5):793-800.  https://doi.org/10.2337/dc14-2585
  48. Ziegler D, Bönhof GJ, Strom A, et al. Progression and Regression of Nerve Fibre Pathology and Dysfunction Early in Diabetes Over 5 Years. Brain. 2021;144(10):3251-3263. https://doi.org/10.1093/brain/awab330
  49. Lozeron P, Nahum L, Lacroix C, et al. Symptomatic Diabetic and Non-Diabetic Neuropathies in a Series of 100 Diabetic Patients. J Neurol. 2002;249(5):569-575.  https://doi.org/10.1007/s004150200066
  50. Gorson KC, Ropper AH. Additional Causes for Distal Sensory Polyneuropathy in Diabetic Patients. J Neurol Neurosurg Psychiatry. 2006;77(3):354-358.  https://doi.org/10.1136/jnnp.2005.075119
  51. Khramilin VN. Differential Diagnosis of Polyneuropathies in Diabetes Mellitus. Medical Council. 2021;(12):256-265. (In Russ.). https://doi.org/10.21518/2079-701X-2021-12-256-265
  52. Ziegler D, Tesfaye S, Spallone V, et al. Screening, Diagnosis and Management of Diabetic Sensorimotor Polyneuropathy in Clinical Practice: International Expert Consensus Recommendations. Diabetes Res Clin Pract. 2022;186:109063. https://doi.org/10.1016/j.diabres.2021.109063
  53. Mayeda L, Katz R, Ahmad I, et al. Glucose Time in Range and Peripheral Neuropathy in Type 2 Diabetes Mellitus and Chronic Kidney Disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. https://doi.org/10.1136/bmjdrc-2019-000991
  54. Yang J, Yang X, Zhao D, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Painful Diabetic Polyneuropathy. J Diabetes Investig. 2021;12(5):828-836.  https://doi.org/10.1111/jdi.13394
  55. Zhang X, Yang X, Sun B, et al. Perspectives of Glycemic Variability in Diabetic Neuropathy: A Comprehensive Review. Commun Biol. 2021;4(1):1366. https://doi.org/10.1038/s42003-021-02896-3
  56. Gad H, Elgassim E, Mohammed I, et al. Continuous Glucose Monitoring Reveals a Novel Association Between Duration and Severity of Hypoglycemia, and Small Nerve Fiber Injury in Patients with Diabetes. Endocr Connect. 2022;11(12):e220352. https://doi.org/10.1530/EC-22-0352
  57. Zangiabadi N, Shafiee K, Alavi KH, et al. Atorvastatin Treatment Improves Diabetic Polyneuropathy Electrophysiological Changes in Non-Insulin Dependent Diabetic Patients: A Double-Blind, Randomized Clinical Trial. Minerva Endocrinol. 2012;37(2):195-200. 
  58. Hernández-Ojeda J, Román-Pintos LM, Rodríguez-Carrízalez AD, et al. Effect of Rosuvastatin on Diabetic Polyneuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study. Diabetes Metab Syndr Obes. 2014;7:401-407.  https://doi.org/10.2147/DMSO.S65500
  59. Villegas-Rivera G, Román-Pintos LM, Cardona-Muñoz EG, et al. Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Oxid Med Cell Longev. 2015;2015:756294. https://doi.org/10.1155/2015/756294
  60. Davis TM, Yeap BB, Davis WA, et al. Lipid-Lowering Therapy and Peripheral Sensory Neuropathy in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetologia. 2008;51(4):562-566.  https://doi.org/10.1007/s00125-007-0919-2
  61. Yoo M, Sharma N, Pasnoor M, et al. Painful Diabetic Peripheral Neuropathy: Presentations, Mechanisms, and Exercise Therapy. J Diabetes Metab. 2013;Suppl 10:005.  https://doi.org/10.4172/2155-6156.S10-005
  62. Look AHEAD Research Group. Effects of a Long-Term Lifestyle Modification Programme on Peripheral Neuropathy in Overweight or Obese Adults With Type 2 Diabetes: The Look AHEAD Study. Diabetologia. 2017;60(6):980-988.  https://doi.org/10.1007/s00125-017-4253-z
  63. Ang CD, Alviar MJ, Dans AL, et al. Vitamin B for Treating Peripheral Neuropathy. Cochrane Database Syst Rev. 2008;(3):CD004573. https://doi.org/10.1002/14651858.CD004573.pub3
  64. Karaganis S, Song XJ. B Vitamins as a Treatment for Diabetic Pain and Neuropathy. J Clin Pharm Ther. 2021;46(5):1199-1212. https://doi.org/10.1111/jcpt.13375
  65. Kukushkin ML. B Vitamins (B1, B6, B12) in the Complex Therapy of Pain Syndromes. Russian Journal of Pain. 2019;17(3):39-45. (In Russ.). https://doi.org/10.25731/RASP.2019.03.31
  66. Kukushkin ML, Suponeva NA, Davydov OS, et al. Expert Panel Opinion: «Possibilities of Cytoflavin in Patients With Diabetic Polyneuropathy» Based on the Results of the Study «Efficacy and Safety of Combined Metabolic Medication Containing Inosine, Nicotinamide, Riboflavin and Succinic Acid, for the Treatment of Diabetic Neuropathy: A Multiple-Center Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Trial (CYLINDER)». Russian Journal of Pain. 2023;21(3):59-65. (In Russ.). https://doi.org/10.17116/pain20232103159
  67. Ametov AS, Barinov AN, Dyck PJ, et al. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved with Alpha-Lipoic Acid. Diabetes Care. 2003;26:770-776. 
  68. Ziegler D, Hanefeld M, Ruhnau RJ, et al. Treatment of Symptomatic Diabetic Peripheral Neuropathy With Antioxidant Alpha-Lipoic Acid: The ALADIN III Study Group. Diabetes Care. 1999;22:1296-1300.
  69. Kojima J, Sugawara Y, Obara S. NIK-247 Blocks Voltage-Dependent Ionic Currents in Crayfish Axon. Jpn J Pharmacol. 1991;57(4):545-552.  https://doi.org/10.1254/jjp.57.545
  70. Kojima J, Onodera K. NIK-247 Induces Long-Term Potentiation of Synaptic Transmission in the CA1 Region of Rat Hippocampal Slices Through M2 Muscarinic Receptors. Gen Pharmacol. 1998;31(2):297-300.  https://doi.org/10.1016/s0306-3623(97)00436-9
  71. Ishii Y, Kojima J, Ikeda N, Kawashima K. Effect of NIK-247 on Basal Concentrations of Extracellular Acetylcholine in the Cerebral Cortex of Conscious, Freely Moving Rats. Jpn J Pharmacol. 1994;66(3):289-293.  https://doi.org/10.1254/jjp.66.289
  72. Kojima J, Onodera K. Effects of NIK-247 and Tacrine on Muscarinic Receptor Subtypes in Rats. Gen Pharmacol. 1998;30(4):537-541.  https://doi.org/10.1016/s0306-3623(97)00303-0
  73. Kojima J, Onodera K, Ozeki M, Nakayama K. Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent. CNS Drug Rev. 1998;4(3):247-259.  https://doi.org/10.1111/j.1527-3458.1998.tb00067.x
  74. Piovesana R, Reid AJ, Tata AM. Emerging Roles of Cholinergic Receptors in Schwann Cell Development and Plasticity. Biomedicines. 2022;11(1):41.  https://doi.org/10.3390/biomedicines11010041
  75. Ockenga W, Kühne S, Bocksberger S, et al. Non-Neuronal Functions of the M2 Muscarinic Acetylcholine Receptor. Genes. 2013;4:171-197.  https://doi.org/10.3390/genes4020171
  76. Naser PV, Kuner R. Molecular, Cellular and Circuit Basis of Cholinergic Modulation of Pain. Neuroscience. 2018;387:135-148.  https://doi.org/10.1016/j.neuroscience.2017.11.038
  77. Lavretskaya EF. Amiridine: a new type of drug stimulants for the nervous and muscular systems. M.: Medeksport. 1989. (In Russ.).
  78. Samartsev IN, Zhivolupov SA, Markova MV, et al. Open-Label Observational Study of Effectiveness and Tolerability of Ipidacrine in Treatment of Patients with Diabetic Polyneuropathy (DIAMANT Study). Neurology and Psychiatry (1). 2024;(2):26-32. (In Russ.). https://doi.org/10.33667/2078-5631-2024-2-26-32
  79. Pashkovskaia NV, Pashkovskii VM, Zorii IA. The Efficiency of Neuromidin in the Comprehensive Treatment of Diabetic Distal Symmetric Polyneuropathy. International Journal of Endocrinology (Ukraine). 2019;15(3):230-235. (In Ukr.). https://doi.org/10.22141/2224-0721.15.3.2019.172109
  80. Malkov AB. Prospective Evaluation of the Effectiveness of Different Methods for Preventing the Progression of Subclinical Diabetic Distal Neuropathy. Medical News. 2018;(7):61-67. (In Russ.).
  81. Romeyko DI, Bilodid IK, Pukita IS, et al. Effectiveness of Neuromidin® in the Treatment of Diabetic Distal Polyneuropathy. Medical News. 2009;6:82-85. (In Russ.).
  82. Dzyak LA, Shulga AN, Tsurkalenko ES, et al. Effectiveness of Neuromidin in the Treatment of Diabetic Polyneuropathy. Ukrainian Bulletin of Psychoneurology. 2007;15(2):135-138. (In Ukr.).
  83. Strokov IA, Zinovyeva OE, Akhmedzhanova LT, et al. Activation of Regeneration and Reinnervation Processes in Diabetic Polyneuropathy. Doctor.Ru. 2008;(4):16-22. (In Russ.).
  84. Kamchatnov PR, Barantsevich ER, Chugunov AV, et al. The Efficacy of Ipidacrine in Patients With Diabetic Polyneuropathy. Nevrologiya, Neiropsikhiatriya, Psikhosomatika=Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):38-43. (In Russ.). https://doi.org/10.14412/2074-2711-2022-3-38-43
  85. Golubovskaya OA, Shkurba AV, Tordia DD, et al. Correction of Polyneuropathy in Type II Diabetes Mellitus in Patients with Chronic Hepatitis C. Clinical Infectology and Parasitology. 2013;1(4):141-150. (In Russ.).
  86. Fedin AI, Solovyova EYu. Results of Russian Multicentre Observational Study of Ipigrix Effect on Motor, Sensory and Cognitive Functions in Patients with Peripheral and Central Nervous System Diseases in Conditions of Actual Clinical Practice. Medical Alphabet. 2018;2(17):9-12. (In Russ.).
  87. Levin OS, Matvievskaya OV. Evaluation of Epidemiological Data on Effect of Therapy With Ipigrix® on Motor and Sensory Functions in Ambulatory Patients With Various Diseases of the Peripheral Nervous System. Medical Alphabet. 2019;1(2):11-14. (In Russ.). https://doi.org/10.33667/2078-5631-2019-1-2(377)-11-14
  88. Rachin AP, Sharov MN, Rachin SA, et al. Observational Study Evaluating the Effectiveness of Ipigrix in Diabetic Polyneuropathy (NIRVANA Study). Nervnye Bolezni. 2018;(2):26-31. (In Russ.).
  89. Kukushkin ML, Karpova MN, Kuznetsova LV, et al. Analgesic effect of ipidacrine. Russian Journal of Pain. 2019;17(3):29-33. (In Russ.). https://doi.org/10.25731/RASP.2019.03.29
  90. Danilov AB, Kukushkin ML, Suponeva NA, et al. Role and place of ipidacrine in the therapy of diseases of the peripheral nervous system. The resolution of the expert council. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):158-164. (In Russ.). https://doi.org/10.17116/jnevro2024124021158
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.